ASCO living guideline (version 2026.1.4) on systemic therapy for metastatic castration-resistant prostate cancer, updated regularly by a standing expert panel that continuously and systematically reviews the literature; the abstract gives no specific recommendations.
Guideline
Taplin et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4